Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s traded shares stood at 1.55 million during the last session, with the company’s beta value hitting 1.37. At the close of trading, the stock’s price was $0.26, to imply a decrease of -1.89% or $0.0 in intraday trading. The PCSA share’s 52-week high remains $3.10, putting it -1092.31% down since that peak but still an impressive 11.54% since price per share fell to its 52-week low of $0.23. The company has a valuation of $1.37M, with an average of 6.37 million shares in intraday trading volume over the past 10 days and average of 1.21 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Processa Pharmaceuticals Inc (PCSA), translating to a mean rating of 2.00. Of 2 analyst(s) looking at the stock, 0 analyst(s) give PCSA a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 2 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.77.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
After registering a -1.89% downside in the last session, Processa Pharmaceuticals Inc (PCSA) has traded red over the past five days. The 5-day price performance for the stock is -16.80%, and -42.36% over 30 days. With these gigs, the year-to-date price performance is -70.58%. Short interest in Processa Pharmaceuticals Inc (NASDAQ:PCSA) saw shorts transact 95265.0 shares and set a 0.93 days time to cover.
The extremes give us $9 and $9 for target low and target high price respectively. As such, PCSA has been trading -3361.54% off suggested target high and -3361.54% from its likely low.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 22.65% for the past 5-year period. While 2025 is set for a 75.19% return in earnings, projections for the next 5 years are at 42.65% annually.
PCSA Dividends
Processa Pharmaceuticals Inc has its next earnings report out on 2025-Mar-19. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders
Processa Pharmaceuticals Inc insiders hold 5.13% of total outstanding shares, with institutional holders owning 1.88% of the shares at 1.98% float percentage. In total, 1.88% institutions holds shares in the company.
